Nov 11 2009
Pfizer China and BMP Sunstone Corporation today announced a strategic partnership to exclusively import, distribute and promote Depo-Provera (Medroxy-progesterone Acetate), a Pfizer product used to treat endometriosis, in China. Endometriosis is a medical condition in women of childbearing age that can cause significant pain.
"This deal establishes a partnership that utilizes BMP Sunstone's unique insight in the women's healthcare market, as well as the company's proven expertise in marketing niche pharmaceutical products to underserved patient populations in China," said Dr. Wu Xiao Bing, Pfizer China Country Manager. "Though it seeks to serve a specially targeted market, this partnership demonstrates Pfizer's commitment to improving the health and well-being of the Chinese people at every stage of their lives."
"We are very excited about our partnership with Pfizer," said Mr. Gao Xiao Ying, CEO and Director of BMP Sunstone. "Depo-Provera is a great addition to our established women's health marketing and distribution portfolio in China. The product has already been approved by the China SFDA, and will be immediately marketable -- benefiting many women who suffer from endometriosis. We are expecting to make Depo-Provera one of the cornerstone products at BMP China, and for it to drive our business growth as we introduce it to the marketplace."
Ovary removal before menopause could accelerate brain degeneration